The antimicrobial drug pipeline has shrunk 35% in five years — from 92 to 60 medicines in development across large pharma companies — according to a report from the Access to Medicine Foundation (AMF), a Netherlands-based non-profit backed by the Wellcome Trust. Only five medicines are in development for children under five, the most vulnerable group. More than 1 million people die directly from drug-resistant infections each year; the infections contribute to 4 million deaths annually. Both figures are forecast to double by 2050 — to nearly 2 million direct deaths and more than 8 million total. The Fleming Initiative predicts up to 10 million deaths from drug-resistant infections by 2050. Jayasree K Iyer, the AMF's chief executive, described drug resistance as 'the biggest single threat to healthcare worldwide.' Claudia Martínez, AMF's director of research, said: 'We don't have enough research going into antimicrobials to outpace resistance.' The market structure explains the retreat. Antibiotics are prescribed for short courses, used sparingly to prevent resistance, and priced low relative to chronic disease drugs. A successful antibiotic is one that sits on the shelf as a reserve weapon — the opposite of a blockbuster revenue model. John-Arne Røttingen, chief executive of the Wellcome Trust, said the lack of effective antibiotics was 'a big challenge for society' and acknowledged that the market for new antibiotics is 'not lucrative for many pharma companies.' This is the core structural problem: the drugs that modern medicine most urgently needs are the drugs that the pharmaceutical business model least rewards. The pipeline isn't shrinking because the science is impossible. It's shrinking because the economics don't close. The concentration is stark. GSK leads with 30 antimicrobial projects — half the entire large pharma pipeline — and is one of just three big companies that continue to invest. The other two are Japan's Shionogi and Otsuka. Pfizer, which was joint first with GSK in 2021, has fallen back. Britain's largest pharmaceutical company, AstraZeneca, isn't even in the ranking because it has no antibiotic portfolio — infectious diseases has never been its focus. The AMF report assesses 25 companies: seven large research-based firms, 10 generic medicine manufacturers, and eight smaller biotechs. The pipeline is not just thin; it is dangerously concentrated in a single company. The resistance data is accelerating. One in six laboratory-confirmed bacterial infections were resistant to antibiotic treatments in 2023, according to the World Health Organization. More than 40% of antibiotics lost potency against common blood, gut, urinary tract and sexually transmitted infections between 2018 and 2023. Ara Darzi — cancer surgeon, lead investigator of the 2024 NHS review, and executive chair of the Fleming Initiative — noted that infection is the second-biggest killer of cancer patients. 'New therapies mean cancer can be fought, but then sadly patients succumb to an infection that was treatable a decade ago,' he said. 'You don't win a game if you have three good strikers and your defence is weak.' The Fleming Initiative is named after Alexander Fleming, who discovered penicillin in London almost 100 years ago. Two policy responses are in motion. The NHS operates a subscription model for antibiotics, paying drugmakers a guaranteed revenue stream regardless of volume — decoupling payment from usage. Røttingen said this model should be adopted by other high-income countries. The European Commission is proposing transferable exclusivity vouchers that would grant antimicrobial drug developers an extra 12 months of data protection — which they could sell to companies with blockbuster drugs, creating a cross-subsidy from profitable drug classes to unprofitable but essential ones. Neither mechanism has been adopted at scale. The bright spots are real but small. In December, the US health regulator approved Innoviva's oral antibiotic Nuzolvence for gonorrhoea and GSK's Blujepa for uncomplicated urinary tract infections and urogenital gonorrhoea — the first antibiotics developed to treat these diseases in decades. Iyer noted three recently approved antibiotics and seven other promising medicines in late-stage development, saying 'it is possible to tilt the battle against superbugs in humanity's favour.' But seven late-stage candidates against a resistance problem affecting 40% of existing antibiotics' potency over five years is not a pipeline that can outpace biology. The arithmetic is directionally clear: resistance is growing faster than replacement. The distributional burden falls hardest on those least able to bear it. People in low- and middle-income countries, where infectious diseases hit hardest, are most vulnerable to drug-resistant superbugs. Iyer emphasised that restricting overuse of antibiotics — including in food production — and managing antibiotic waste responsibly were also critical. The extraction map runs from global populations to pharmaceutical shareholders: the business model that rewards chronic disease drugs over antibiotics is not a conspiracy, but it is a structural choice that transfers risk from corporate balance sheets to public health systems, with the heaviest costs borne by the poorest populations.